Transcenta Holding Limited (HKG:6628)

Hong Kong · Delayed Price · Currency is HKD

2.650

-0.070 (-2.57%)

Apr 17, 2026, 4:08 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
The Discovering, Developing, Manufacturing and Commercializing Novel Drugs		11.26M	53.85M	101.89M	50.24M	80.98M
The Discovering, Developing, Manufacturing and Commercializing Novel Drugs Growth		-79.09%	-47.15%	102.80%	-37.96%	83.46%
Total		11.26M	53.85M	101.89M	50.24M	80.98M
Total Growth		-79.09%	-47.15%	102.80%	-37.96%	83.46%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
PRC		11.26M	53.85M	101.89M	50.24M	80.98M
PRC Growth		-79.09%	-47.15%	102.80%	-37.96%	83.46%
Total		11.26M	53.85M	101.89M	50.24M	80.98M
Total Growth		-79.09%	-47.15%	102.80%	-37.96%	83.46%

Source: S&P Global Market Intelligence.